domingo, 24 de marzo de 2019

Gene and cell therapies offer ground-breaking new opportunities for patients with rare and complex diseases.

Rare Impact

Eurordis, Rare Diseases Europe

QUÉ ES NUEVO EN EURORDIS?



Gene and cell therapies offer ground-breaking new opportunities for patients with rare and complex diseases.

Maximizing patient access to effective gene and cells therapies is a part of the Rare Impact initiative's mission.

30 million Europeans are living with rare diseases and 80% of rare diseases are genetic in origin.
There are many challenges hampering patients’ access to gene and cell therapies; to date, the availability of these therapies is limited.

 Gene and cell therapy availability – Feb '19

  • Withdrawn from market
  • Available in > 3 European markets
  • Available in < 3 European markets
EURORDIS has initiated a patient-focused collaboration that seeks to improve patients’ access to these therapies.

No hay comentarios: